Literature DB >> 25124105

Accuracy of nimodipine gel extraction.

Douglas R Oyler1, Sarah E Stump, Aaron M Cook.   

Abstract

INTRODUCTION: Until recently, use of nimodipine in aneurysmal subarachnoid hemorrhage patients unable to swallow required extraction of gel from inside the commercially available capsule. Despite the Black-Box warning against inadvertent intravenous administration, bedside extraction of the gel from the capsule continues to be a common practice in some institutions. The accuracy of bedside extraction has not been formally evaluated.
METHODS: Twenty-eight nurses from the neurology and neurosurgical ICUs at a single center attempted to extract nimodipine gel from 2 capsules, each using the method currently approved by the US FDA. The primary outcome was mean weight of extracted gel per capsule, which was compared to both gel weight from batch compounded pharmacy syringes and a pre-calculated appropriate weight for 30 mg nimodipine gel.
RESULTS: Simulated bedside extraction provided lower yield than pharmacy-compounded syringes (22.6 ± 4.6 mg vs 30.4 ± 0.59 mg, p = 0.001). Bedside extraction provided inconsistent and low yield (75.4 ± 15.32 % of possible dose extracted, p = 0.0001 for comparison of means between bedside extraction syringes and predicted gel weight). Pharmacy-compounded syringes provided consistent high yield (101.3 ± 2.0 % of possible dose extracted, p = 0.14 for comparison of means between pharmacy syringes and predicted gel weight).
CONCLUSION: Combined with reports of significant patient harm and death with inadvertent intravenous administration, this study suggests that there is no role for bedside extraction of nimodipine in clinical practice.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25124105     DOI: 10.1007/s12028-014-0054-0

Source DB:  PubMed          Journal:  Neurocrit Care        ISSN: 1541-6933            Impact factor:   3.210


  10 in total

1.  Stability of nimodipine solution in oral syringes.

Authors:  Amy E Green; Stan Banks; Michael Jay; Jimmi Hatton
Journal:  Am J Health Syst Pharm       Date:  2004-07-15       Impact factor: 2.637

2.  ISMP Medication Error Report Analysis.

Authors: 
Journal:  Hosp Pharm       Date:  2013-06

3.  Multivariate analysis of predictors of cerebral vasospasm occurrence after aneurysmal subarachnoid hemorrhage.

Authors:  C Charpentier; G Audibert; F Guillemin; T Civit; X Ducrocq; S Bracard; H Hepner; L Picard; M C Laxenaire
Journal:  Stroke       Date:  1999-07       Impact factor: 7.914

Review 4.  Prediction of cerebral vasospasm in patients presenting with aneurysmal subarachnoid hemorrhage: a review.

Authors:  Christopher G Harrod; Bernard R Bendok; H Hunt Batjer
Journal:  Neurosurgery       Date:  2005-04       Impact factor: 4.654

Review 5.  Cerebral vasospasm following aneurysmal subarachnoid hemorrhage.

Authors:  N F Kassell; T Sasaki; A R Colohan; G Nazar
Journal:  Stroke       Date:  1985 Jul-Aug       Impact factor: 7.914

Review 6.  Stroke epidemiology: a review of population-based studies of incidence, prevalence, and case-fatality in the late 20th century.

Authors:  Valery L Feigin; Carlene M M Lawes; Derrick A Bennett; Craig S Anderson
Journal:  Lancet Neurol       Date:  2003-01       Impact factor: 44.182

7.  Nimodipine treatment in poor-grade aneurysm patients. Results of a multicenter double-blind placebo-controlled trial.

Authors:  K C Petruk; M West; G Mohr; B K Weir; B G Benoit; F Gentili; L B Disney; M I Khan; M Grace; R O Holness
Journal:  J Neurosurg       Date:  1988-04       Impact factor: 5.115

8.  Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid haemorrhage: British aneurysm nimodipine trial.

Authors:  J D Pickard; G D Murray; R Illingworth; M D Shaw; G M Teasdale; P M Foy; P R Humphrey; D A Lang; R Nelson; P Richards
Journal:  BMJ       Date:  1989-03-11

Review 9.  Cerebral vasospasm after aneurysmal subarachnoid hemorrhage: an overview of pharmacologic management.

Authors:  Xi Liu-Deryke; Denise H Rhoney
Journal:  Pharmacotherapy       Date:  2006-02       Impact factor: 4.705

Review 10.  Nimodipine and its use in cerebrovascular disease: evidence from recent preclinical and controlled clinical studies.

Authors:  Daniele Tomassoni; Alessia Lanari; Giorgio Silvestrelli; Enea Traini; Francesco Amenta
Journal:  Clin Exp Hypertens       Date:  2008-11       Impact factor: 1.749

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.